tirzepatide cvot trial SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide

In respiratory models, GHK has been noted for potential involvement in gene expression changes linked to injury recovery

Medical supervision also allows the safe addition of complementary prescription appetite suppressants, if necessary or beneficial

Chen WP, Xiong Y, Shi YX, Hu PF, Bao JP, Wu LD (2014) Astaxanthin reduces matrix metalloproteinase expression in human chondrocytes

Labat, C

Establishing consistent sleep-wake times, creating a relaxing bedtime routine, and optimising your sleep environment (cool, dark, and quiet) can support healthy metabolic function

Check your metabolic health daily and get tailored advice from an AI companion